E-base: Medgend

AKNE-MYCIN [Erythromycin^{C₃₇H₆₇NO₁₃}]

RX

-

2% (topical ointment)

Dow Pharm^{Jan 10, 1985}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

ERY-TAB [Erythromycin^{C₃₇H₆₇NO₁₃}]

RX

-

250mg (oral tablet, delayed release)

333mg (oral tablet, delayed release)

500mg (oral tablet, delayed release)

Arbor Pharms Llc^{Approved Prior To Jan 1, 1982}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

ERYC [Erythromycin^{C₃₇H₆₇NO₁₃}]

RX

-

250mg (oral capsule, delayed rel pellets)

Mayne Pharma^{Approved Prior To Jan 1, 1982}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

ERYGEL [Erythromycin^{C₃₇H₆₇NO₁₃}]

RX

-

2% (topical gel)

Mylan Pharms Inc^{Oct 21, 1987}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

ERYTHROMYCIN [Erythromycin^{C₃₇H₆₇NO₁₃}]

RX

-

0.5% (ophthalmic ointment)

2% (topical swab)

250mg (oral tablet)

500mg (oral tablet)

Akorn^{Jul 18, 1996}
Bausch And Lomb^{Jul 29, 1994}
Perrigo Co Tennessee^{Sep 26, 1983}
Fougera Pharms^{Sep 30, 1997}
Perrigo New York^{Jan 11, 1991}
Wockhardt^{Oct 23, 1987}
Arbor Pharms Llc^{Approved Prior To Jan 1, 1982}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

KISQALI [Ribociclib Succinate^{C₂₃H₃₀N₈OC₄H₆O₄}]

RX

-

eq 200mg base (oral tablet)

Novartis Pharms Corp^{Mar 13, 2017}

In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

KISQALI FEMARA CO-PACK (COPACKAGED) [Letrozole^{C₁₇H₁₁N₅} : Ribociclib Succinate^{C₂₃H₃₀N₈OC₄H₆O₄}]

RX

-

2.5mg,n/a : n/a,eq 200mg base (oral tablet, tablet)

Novartis Pharms Corp^{May 4, 2017}

In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

ONIVYDE [Irinotecan Hydrochloride^{C₃₃H₃₈N₄O₆ClH3H₂O}]

RX

-

eq 43mg base/10ml (eq 4.3mg base/ml) (iv (infusion) injectable, liposomal)

Ipsen Inc^{Oct 22, 2015}

Treatment of exocrine pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin.
Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin, in a patient homozygous for the ugt1a1*28 allele.
Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin.
Treatment of pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin.
Treatment of pancreatic cancer.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

PCE [Erythromycin^{C₃₇H₆₇NO₁₃}]

RX

-

333mg (oral tablet, coated particles)

500mg (oral tablet, coated particles)

Arbor Pharms Llc^{Sep 9, 1986}

Ledgend of Medicine

MODERN MEDICINES

HOME REMEDIES

RANDOM DRUGS

RANDOM AILMENTS

E-base FDA Approved Drugs